KemPharm, Inc. (KMPH) Receives Average Rating of “Buy” from Analysts
KemPharm, Inc. (NASDAQ:KMPH) has been given a consensus rating of “Buy” by the six research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $9.00.
A number of equities research analysts have issued reports on KMPH shares. Roth Capital started coverage on KemPharm in a research report on Wednesday, June 28th. They set a “buy” rating and a $8.00 target price for the company. ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 1st. Zacks Investment Research raised KemPharm from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Canaccord Genuity reaffirmed a “buy” rating and set a $7.00 target price on shares of KemPharm in a research report on Monday, September 11th. Finally, Oppenheimer Holdings, Inc. set a $13.00 target price on KemPharm and gave the stock a “buy” rating in a research report on Thursday, August 10th.
KemPharm (KMPH) opened at 3.85 on Wednesday. KemPharm has a 12 month low of $2.45 and a 12 month high of $5.40. The firm’s 50-day moving average is $3.42 and its 200-day moving average is $3.77. The firm’s market capitalization is $56.43 million.
KemPharm (NASDAQ:KMPH) last announced its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.19. On average, equities research analysts expect that KemPharm will post ($2.72) EPS for the current year.
In related news, major shareholder Delaware Street Capital Master bought 325,888 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was purchased at an average price of $3.27 per share, with a total value of $1,065,653.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have acquired 335,188 shares of company stock valued at $1,090,088 in the last ninety days. Company insiders own 22.80% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in shares of KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock valued at $112,000 after acquiring an additional 3,414 shares during the period. Victory Capital Management Inc. bought a new stake in shares of KemPharm in the first quarter valued at approximately $647,000. Finally, C WorldWide Group Holding A S boosted its position in shares of KemPharm by 110.1% in the second quarter. C WorldWide Group Holding A S now owns 381,699 shares of the specialty pharmaceutical company’s stock valued at $1,527,000 after acquiring an additional 200,000 shares during the period. 40.01% of the stock is owned by institutional investors.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.